EGFR and non-small cell lung carcinoma: Several clinical trials have clearly demonstrated that tyrosine kinase inhibitors (TKI) of the epidermal growth factor receptor (EGFR) have achieved improved clinical outcomes for EGFR mutant (EGFRm) NSCLC patients (3–6).